IXSCIENT LIMITED

Their core work

Ixscient is a UK-based SME specializing in digital health technologies, particularly the development and validation of digital biomarkers and endpoints for clinical research. They provide data science and digital measurement expertise to large clinical consortia, helping translate sensor-based and digital assessments into regulatory-grade clinical outcomes. Their work spans liver disease diagnostics, mobility monitoring, and fatigue/sleep measurement in neurodegenerative and inflammatory conditions.

What they specialise in

How they've shifted over time

Ixscient's early H2020 work (2015-2017) focused on traditional diagnostics and disease pathology — sepsis detection platforms (RAIS) and liver disease mechanisms (EPoS, LITMUS). From 2019 onward, they shifted decisively toward digital health, joining major consortia on digital mobility assessment (MOBILISE-D) and digital endpoints for fatigue and sleep (IDEA-FAST). This trajectory shows a clear pivot from lab-based diagnostics to wearable-driven, real-world digital measurement for clinical trials.

Ixscient is moving firmly into digital endpoint validation and regulatory-grade digital biomarkers — expect them to pursue projects on wearable-derived clinical outcomes and decentralized clinical trials.

How they like to work

Ixscient operates exclusively as a participant, never coordinating, which suggests they provide specialized technical capabilities that large consortia need but don't lead the clinical agenda themselves. With 147 unique partners across 21 countries from just 5 projects, they consistently join very large, multi-stakeholder research consortia. This pattern indicates they are a trusted specialist contributor that major clinical networks invite when they need digital measurement or data science expertise.

Despite only 5 projects, Ixscient has built an extensive network of 147 unique partners across 21 countries, reflecting their participation in large-scale clinical research consortia with pan-European reach. Their network spans major academic medical centers, pharma companies, and regulatory bodies involved in clinical endpoint validation.

What sets them apart

Ixscient occupies a niche at the intersection of digital technology and clinical research that few SMEs can claim — they bridge the gap between raw sensor data and clinically meaningful, regulatory-acceptable endpoints. Their progression from traditional diagnostics to digital health gives them dual fluency in both lab-based and digital measurement approaches. For consortium builders, they offer a nimble SME partner that understands both the technology and the clinical validation pathway.

Highlights from their portfolio

• MOBILISE-D
  Largest funding (EUR 464K) and a flagship IMI-style consortium connecting digital mobility measurement to clinical and regulatory endorsement across multiple disease areas.
• IDEA-FAST
  Long-running project (2019-2026) tackling digital endpoints for fatigue and sleep — a frontier area where no validated digital biomarkers yet exist.
• LITMUS
  Major NAFLD biomarker validation study bridging Ixscient's earlier liver disease work with their growing digital measurement expertise.